Group 1 - The core viewpoint of the news is that the China Securities Regulatory Commission (CSRC) has issued additional requirements for the overseas listing application of Xiantong International, focusing on compliance and operational status [1] - Xiantong International is a leader in the Chinese radiopharmaceutical market, aiming to develop and commercialize innovative radiopharmaceuticals with the potential to be the first listed in China [2] - The company has a pipeline focusing on oncology, neurodegenerative diseases, and cardiovascular diseases, including 15 assets and four core products [2] Group 2 - Financially, Xiantong International reported revenues of approximately RMB 10.23 million and RMB 44.06 million for the fiscal years 2023 and 2024, respectively [2] - The company incurred losses of approximately RMB 309 million and RMB 156 million for the same periods [2] - The CSRC has requested clarification on the reasonableness of the share prices for new shareholders and their potential impact on the independence of the underwriting institutions [1]
先通国际拟港股IPO 中国证监会要求说明公司生产线是否实际投入使用及相关合规性情况
Zhi Tong Cai Jing·2025-07-11 11:09